Study links prenatal immune activity to Alzheimer’s risk in later life

Findings from a Mass General Brigham-led study that has followed participants since before birth may offer clues about the origins of Alzheimer’s disease.

With subpar sales for Leqembi, Eisai delays Alzheimer’s patient goal deadline

Eisai said it could struggle to meet uptake targets for its Biogen-partnered Alzheimer’s drug Leqembi by the end of March as it detailed disappointing fiscal

February 7, 2024

Japan accepts for review GSK’s Nucala application

GSK’s sJNDA for Nucala to treat rhinosinusitis has been accepted for review in Japan. Credit: GSK. The Japanese Ministry of Health, Labour and Welfare (MHLW)

September 4, 2023

argenx enrols new cohort in Phase II multifocal motor neuropathy study – Pharmaceutical Technology

Immune globulin treatments are the only available MMN therapies – but ARGX-117 could change that. Source: Shutterstock / Kateryna Kon. Netherlands-based immunology company Argenx has

June 20, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.